News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Agensys, Inc., an Affiliate of Astellas Pharma Inc. (YPH.BE), and Seattle Genetics, Inc. (SGEN) Announce Initiation of Phase I Clinical Trial of ASG-5ME for Prostate Cancer


10/20/2010 10:27:54 AM

SANTA MONICA, Calif. & BOTHELL, Wash.--(BUSINESS WIRE)--Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that they have initiated a phase I clinical trial of ASG-5ME for the treatment of castration-resistant prostate cancer. ASG-5ME is an antibody-drug conjugate (ADC) targeting the SLC44A4 antigen and is being co-developed by both companies for the treatment of solid tumors.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES